UK markets closed

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
97.130.00 (0.00%)
As of 11:43AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close97.13
Open100.20
Bid0.00 x 0
Ask0.00 x 0
Day's range97.13 - 97.13
52-week range88.75 - 112.65
Volume26
Avg. volume6,812
Market cap121.919B
Beta (5Y monthly)0.40
PE ratio (TTM)18.04
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield3.86 (3.97%)
Ex-dividend date05 May 2021
1y target estN/A
All
News
  • Globe Newswire

    Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes

    Availability of the Q3 2021 Memorandum for modelling purposes Paris, France – September 24, 2021 - Sanofi announced today that its Q3 2021 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q3-results-2021 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on variou

  • Globe Newswire

    New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV

    New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents, and adults Results provide insight into the clinical and real-world experience of Dupixent on key disease measures including itch, disease severity, sleep and anxietyDupixent pr

  • Globe Newswire

    ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC

    ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC Phase 3 trial met its primary and key secondary endpointsLibtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with chemotherapyTrial enrolled patients with varied baseline characteristics, including squamo